The additive effect of timolol on open angle glaucoma patients on maximal medical therapy.
Thirty-one eyes of 20 glaucomatous patients on maximum medication were treated with timolol drops for a mean period of 9 months. Adequate levels of control of intraocular pressures were obtained in 21 eyes. No significant ocular or systemic side effects were noted. Timolol has an additive effect in further lowering intraocular pressures in patients being treated with a combination of carbonic anhydrase inhibitors, pilocarpine, epinephrine, and the anticholinesterases.
D000328:Adult; D000368:Aged; D002256:Carbonic Anhydrases / Q000008:administration & dosage; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004837:Epinephrine / Q000008:administration & dosage; D005260:Female; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D010862:Pilocarpine / Q000008:administration & dosage; D011412:Propanolamines / Q000627:therapeutic use*; D013999:Timolol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D002800:Cholinesterase Inhibitors; D011412:Propanolamines; D010862:Pilocarpine; D013999:Timolol; D002256:Carbonic Anhydrases; D004837:Epinephrine